VivoSim Labs, Inc. Payments To Acquire Equity Securities Fv Ni
VivoSim Labs, Inc. (VIVS) reported Payments To Acquire Equity Securities Fv Ni of $0 for the 12-month period ending 2024-03-31, per its 10-K filed 2024-05-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquitySecuritiesFvNi · last filed 2024-05-31
- VivoSim Labs, Inc. payments to acquire equity securities fv ni for the quarter ending 2024-03-31 was $0.00.
- VivoSim Labs, Inc. payments to acquire equity securities fv ni for the quarter ending 2023-12-31 was $0.00.
- VivoSim Labs, Inc. payments to acquire equity securities fv ni for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- VivoSim Labs, Inc. payments to acquire equity securities fv ni for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- VivoSim Labs, Inc. payments to acquire equity securities fv ni for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- VivoSim Labs, Inc. payments to acquire equity securities fv ni for fiscal 2023 was $1.06M.
- VivoSim Labs, Inc. payments to acquire equity securities fv ni for fiscal 2022 was $0.00.
| Period end | Payments To Acquire Equity Securities Fv Ni 3 month | Payments To Acquire Equity Securities Fv Ni 6 month | Payments To Acquire Equity Securities Fv Ni 9 month | Payments To Acquire Equity Securities Fv Ni 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-31 | $0.00 derived: sum of 2 quarters · filed 2024-05-31 | $0.00 derived: sum of 3 quarters · filed 2024-05-31 | $0.00 10-K · filed 2024-05-31 |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08 | $0.00 derived: sum of 2 quarters · filed 2024-02-08 | $0.00 10-Q · filed 2024-02-08 | $0.00 derived: sum of 4 quarters · filed 2024-05-31 |
| 2023-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 3 quarters · filed 2024-05-31 | $0.00 derived: sum of 4 quarters · filed 2024-05-31 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 2 quarters · filed 2024-05-31 | $0.00 derived: sum of 3 quarters · filed 2024-05-31 | $333.00K derived: sum of 4 quarters · filed 2024-05-31 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-31 | $0.00 derived: sum of 2 quarters · filed 2024-05-31 | $333.00K derived: sum of 3 quarters · filed 2024-05-31 | $1.06M 10-K · filed 2024-05-31 |
| 2022-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08 | $333.00K derived: sum of 2 quarters · filed 2024-02-08 | $1.06M 10-Q · filed 2024-02-08 | $1.06M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | $333.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | $1.06M 10-Q · filed 2023-11-09 | $1.06M derived: sum of 3 quarters · filed 2023-11-09 | $1.06M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $728.00K 10-Q · filed 2023-08-10 | $728.00K derived: sum of 2 quarters · filed 2023-08-10 | $728.00K derived: sum of 3 quarters · filed 2023-08-10 | $728.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-14 | $0.00 derived: sum of 2 quarters · filed 2023-07-14 | $0.00 derived: sum of 3 quarters · filed 2023-07-14 | $0.00 10-K · filed 2023-07-14 |
| 2021-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09 | $0.00 derived: sum of 2 quarters · filed 2023-02-09 | $0.00 10-Q · filed 2023-02-09 | |
| 2021-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |